migraine. Migraine
Conditions
Interventions
Intervention 1: Intervention group: The intervention group will receive Lacosamide medication daily at a dose of 50 mg provided by Actover Company for a duration of three months. Intervention 2: Inter
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: The patients' age should be between 18 and 45 years They must have migraine disease according to the ICHD-3 criteria They must not have used migraine preventive medication in the past month The patient must have the ability to respond to questions
Exclusion criteria
Exclusion criteria: Lack of patient consent to participate in the study Lacosamide medication interfere with other drugs received by the patient
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Migraine duration. Timepoint: Month. Method of measurement: Ask the patient.;Migraine intensity. Timepoint: Baseline (before treatment) and after 3 months. Method of measurement: MIDAS questionnaire, completed by patients.;The concentration of Calcitonin Gene-Related Peptide (CGRP-LI) in the blood, linked to migraine. Timepoint: Baseline (before treatment) and after 3 months. Method of measurement: ELISA test. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactIman Kiani
Tehran University of Medical Sciences
Outcome results
None listed